BAAM
NMTC icon

Baker Avenue Asset Management’s NeuroOne Medical Technologies NMTC Stock Holding History

Baker Avenue Asset Management’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-29,895
Closed -$1.19M – 270
2021
Q2 		$1.19M Buy
+29,895
New +$1.26M 0.07% 137

Other funds holding NMTC

Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IC
Intersect Capital San Ramon, California $331M AUM 6.79% 1-Year Est. Return
PAM
Premier Asset Management Chicago, Illinois $79.6M AUM 10.77% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CG
Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Baker Avenue Asset Management's NMTC Position: Q3 2021 in Review

Baker Avenue Asset Management sold out of NeuroOne Medical Technologies (NMTC) in Q3 2021, closing a stake of 29,895 shares — an estimated $1.19M sold.

Baker Avenue Asset Management first reported a position in NMTC in Q2 2021 and held it in 1 quarter. The position peaked at $1.19M in Q2 2021. 7 funds tracked by Wall St. Rank hold NMTC as of Q3 2021.

  • Baker Avenue Asset Management reported no remaining NeuroOne Medical Technologies position as of Q3 2021 after selling out during the quarter.
  • Baker Avenue Asset Management sold 29,895 NeuroOne Medical Technologies shares in Q3 2021, an estimated $1.19M.
  • Baker Avenue Asset Management first reported a position in NeuroOne Medical Technologies in Q2 2021 and held it in 1 quarter.
  • Baker Avenue Asset Management's NeuroOne Medical Technologies position peaked at $1.19M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q3 2021.

Based on Baker Avenue Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.